JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Pfizer

Chiusa

SettoreSettore sanitario

24.59 0.04

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

24.55

Massimo

24.91

Metriche Chiave

By Trading Economics

Entrata

2.6B

3B

Vendite

-4B

14B

P/E

Media del settore

17.051

34.393

EPS

0.92

Rendimento da dividendi

7.19

Margine di Profitto

21.677

Dipendenti

81,000

EBITDA

2.5B

5.1B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+16.31% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

7.19%

2.54%

Utili prossimi

28 ott 2025

Prossima data del Dividendo

2 set 2025

Prossima data del' Ex Dividendo

7 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-12B

134B

Apertura precedente

24.55

Chiusura precedente

24.59

Notizie sul Sentiment di mercato

By Acuity

39%

61%

125 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Pfizer Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 ago 2025, 11:34 UTC

Utili

Pfizer Boosts 2025 Adjusted EPS Outlook Following 2Q Gains

5 ago 2025, 20:44 UTC

Utili

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 ago 2025, 18:20 UTC

Utili

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5 ago 2025, 18:17 UTC

Utili

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 ago 2025, 16:04 UTC

Discorsi di Mercato

Pfizer's New Tax Rate Helps Boost Adj EPS Outlook -- Market Talk

5 ago 2025, 15:25 UTC

Utili

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 ago 2025, 13:56 UTC

Utili

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5 ago 2025, 11:43 UTC

Utili

Pfizer Stock Pops as Earnings Smash Expectations. Guidance Hiked in Face of Tariffs. -- Barrons.com

5 ago 2025, 11:27 UTC

Utili

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 ago 2025, 10:57 UTC

Utili

Pfizer Stock Pops as Earnings Smash Expectations. Why the Outlook Has Been Hiked. -- Barrons.com

5 ago 2025, 10:55 UTC

Utili

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 ago 2025, 10:53 UTC

Utili

Pfizer Boosts 2025 Profit Estimate In A Sign Of 'Confidence' -- MarketWatch

5 ago 2025, 10:51 UTC

Utili

Pfizer: On Track to Deliver About $7.2B Overall Cost Savings From Cost-Improvement Initiatives b/ End of 2027 >PFE

5 ago 2025, 10:50 UTC

Utili

Pfizer: Expects to Continue to De-Lever in Prudent Manner to Maintain Balanced Capital-Allocation Strategy >PFE

5 ago 2025, 10:49 UTC

Utili

Pfizer: Current Financial Guidance Doesn't Anticipate Any Share Repurchases in 2025 >PFE

5 ago 2025, 10:49 UTC

Utili

Pfizer Now Sees 2025 Effective Tax Rate on Adjusted Income About 13%; Had Seen About 15% >PFE

5 ago 2025, 10:48 UTC

Utili

Pfizer Cuts Adjusted R&D Expenses View to $10.4-$11.4B From $10.7B-$11.7B >PFE

5 ago 2025, 10:48 UTC

Utili

Pfizer: Guidance Absorbs Impact of Potential Price Changes This Year Based on Letter Received July 31 From President Trump >PFE

5 ago 2025, 10:47 UTC

Utili

Pfizer: Guidance Absorbs Impact of Currently Imposed Tariffs From China, Canada, Mexico >PFE

5 ago 2025, 10:46 UTC

Utili

Pfizer Had Seen 2025 Adjusted EPS $2.80-$3.00 >PFE

5 ago 2025, 10:45 UTC

Utili

Pfizer Raises 2025 EPS Guidance >PFE

5 ago 2025, 10:45 UTC

Utili

Pfizer 2Q EPS 51c >PFE

5 ago 2025, 10:45 UTC

Utili

Pfizer Sees FY Adj EPS $2.90-Adj EPS $3.10 >PFE

5 ago 2025, 10:45 UTC

Utili

Pfizer 2Q Adj EPS 78c >PFE

5 ago 2025, 10:45 UTC

Utili

Pfizer 2Q Rev $14.7B >PFE

5 ago 2025, 10:45 UTC

Utili

Pfizer Sees FY Rev $61B-$64B >PFE

4 ago 2025, 15:26 UTC

Utili

Pfizer Reports Earnings Soon. The Stock Is Slumping for a Reason. -- Barrons.com

30 lug 2025, 18:36 UTC

Utili

UPS Stock Joins 7% Yielders in S&P 500. Here's Who Else Is in the Club. -- Barrons.com

9 lug 2025, 09:17 UTC

Azioni calde

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

10 giu 2025, 12:18 UTC

Utili

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Pfizer Previsione

Obiettivo di Prezzo

By TipRanks

16.31% in crescita

Previsioni per 12 mesi

Media 28.59 USD  16.31%

Alto 33 USD

Basso 24 USD

Basato su 18 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Pfizer - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

18 ratings

6

Acquista

12

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

22.855 / 23.85Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

125 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.